Monograph Details
|
|
Respiratory Tract
> Lung surfactants/mucolytics
|
|
PULMOZYME |
| Manufacturer |
|
Genentech, Inc. |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Dornase alfa (recombinant human DNase) 1mg/mL; soln for inh; preservative-free. |
| Indications |
|
Management of cystic fibrosis in conjunction with standard therapies to improve pulmonary function. |
| Adults and Children |
|
<3months: not recommended. Use appropriate nebulizer. Do not dilute. >5yrs: 2.5mg once daily via nebulization; may increase to 2.5mg twice daily (see literature). |
| Precautions |
|
For patients <5yrs of age, use only if there is a potential for benefit in pulmonary function or in risk of respiratory tract infection. Use only with recommended nebulizers. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Do not mix with other drugs in nebulizer. |
| Adverse Reactions |
|
Pharyngitis, voice alteration, laryngitis, rash, chest pain, conjunctivitis. |
| How Supplied |
|
Amps (2.5mL)—30 |
|
|
|
|
